EP2306825A4 - Inhibiteurs de l'activité de l'akt - Google Patents

Inhibiteurs de l'activité de l'akt

Info

Publication number
EP2306825A4
EP2306825A4 EP09770904A EP09770904A EP2306825A4 EP 2306825 A4 EP2306825 A4 EP 2306825A4 EP 09770904 A EP09770904 A EP 09770904A EP 09770904 A EP09770904 A EP 09770904A EP 2306825 A4 EP2306825 A4 EP 2306825A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
akt activity
akt
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09770904A
Other languages
German (de)
English (en)
Other versions
EP2306825A1 (fr
Inventor
Hong Lin
Meagan B Rouse
Mark A Seefeld
Dennis S Yamashita
Ren Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of EP2306825A1 publication Critical patent/EP2306825A1/fr
Publication of EP2306825A4 publication Critical patent/EP2306825A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09770904A 2008-06-26 2009-06-24 Inhibiteurs de l'activité de l'akt Withdrawn EP2306825A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7584308P 2008-06-26 2008-06-26
PCT/US2009/048373 WO2009158371A1 (fr) 2008-06-26 2009-06-24 Inhibiteurs de l'activité de l'akt

Publications (2)

Publication Number Publication Date
EP2306825A1 EP2306825A1 (fr) 2011-04-13
EP2306825A4 true EP2306825A4 (fr) 2011-12-28

Family

ID=41444907

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09770904A Withdrawn EP2306825A4 (fr) 2008-06-26 2009-06-24 Inhibiteurs de l'activité de l'akt

Country Status (4)

Country Link
US (1) US20110129455A1 (fr)
EP (1) EP2306825A4 (fr)
JP (1) JP2011525928A (fr)
WO (1) WO2009158371A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
RS58718B1 (sr) 2011-05-12 2019-06-28 Proteostasis Therapeutics Inc Regulatori proteostaze
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
JP6321042B2 (ja) 2013-02-06 2018-05-09 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規なハロゲン置換された化合物
CA2928568A1 (fr) 2013-07-26 2015-01-29 Update Pharma Inc. Procedes combinatoires permettant d'ameliorer l'avantage therapeutique du bisantrene
WO2015073528A1 (fr) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Composés renforçant l'activité des protéasomes
KR20160104065A (ko) 2014-01-03 2016-09-02 바이엘 애니멀 헬스 게엠베하 농약으로서의 신규 피라졸릴헤테로아릴아미드
JP6900406B2 (ja) 2016-06-16 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
US11261196B2 (en) 2017-12-13 2022-03-01 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt serving as AKT inhibitor and crystal thereof
WO2020078865A1 (fr) 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs d'akt en ophtalmologie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041687B2 (en) * 2002-01-25 2006-05-09 Vertex Pharmaceuticals Incorporated Indazole compounds useful as protein kinase inhibitors
WO2007058852A2 (fr) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibiteurs de l’activite de l’akt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145757A (en) * 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
JP4357295B2 (ja) * 2001-08-03 2009-11-04 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターとその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041687B2 (en) * 2002-01-25 2006-05-09 Vertex Pharmaceuticals Incorporated Indazole compounds useful as protein kinase inhibitors
WO2007058852A2 (fr) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibiteurs de l’activite de l’akt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009158371A1 *

Also Published As

Publication number Publication date
WO2009158371A8 (fr) 2011-01-27
WO2009158371A1 (fr) 2009-12-30
US20110129455A1 (en) 2011-06-02
JP2011525928A (ja) 2011-09-29
EP2306825A1 (fr) 2011-04-13

Similar Documents

Publication Publication Date Title
IL200212A0 (en) Inhibitors of akt activity
IL209488A0 (en) Inhibitors of akt activity
EP2114388A4 (fr) Inhibiteurs de l'activité de akt
EP2303852A4 (fr) Inhibiteurs d activité akt
ZA201700326B (en) Inhibitors of beta-secretase
IL190968A0 (en) Inhibitors of akt activity
EP1968568A4 (fr) INHIBITEURS D'ACTIVITE Akt
IL187690A0 (en) Inhibitors of akt activity
EP2134175A4 (fr) Inhibiteurs de l'activité de akt
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL220153A0 (en) Inhibitors of akt activity
SG10201404913QA (en) Inhibitors of cognitive decline
IL217833A0 (en) Inhibitors of cognitive decline
GB0811091D0 (en) CYP26 Inhibitors
EP2303277A4 (fr) Inhibiteurs de l'activité de l'akt
EP2303017A4 (fr) Inhibiteurs d activité akt
EP2303258A4 (fr) Inhibiteurs d activité akt
GB0817429D0 (en) Enzyme inhibitors
EP1948185A4 (fr) Inhibiteurs de l'activite de l'akt
GB2452842B (en) Method of increasing activity
HK1166320A (en) Inhibitors of beta-secretase
TH0801000575A (th) บรรดาตัวยับยั้งของการออกฤทธิ์ Akt
GB0803895D0 (en) Inhibitors of glyoxalase
HK1129677A (zh) Akt活性抑制劑
GB0908609D0 (en) New use of isoQC inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20111118BHEP

Ipc: C07D 231/38 20060101ALI20111118BHEP

Ipc: A61K 9/20 20060101ALI20111118BHEP

Ipc: A61K 9/16 20060101ALI20111118BHEP

Ipc: A61K 31/40 20060101ALI20111118BHEP

Ipc: A01N 43/36 20060101AFI20111118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120626